Business Wire

OR-GUROBI-OPTIMIZATION

2.6.2022 23:28:10 CEST | Business Wire | Press release

Share
Gurobi Unveils New Interactive Educational Game Highlighting the Power of Optimization

Gurobi Optimization, LLC , creator of the world’s fastest mathematical optimization solver, announced the launch of their new educational game that aims to show players the power of optimization. The “Burrito Optimization Game” is a free, web-based app designed for data science and operations research students, as well as anyone who stands to benefit from mathematical optimization. In addition to demonstrating the value of optimization, the game also proves its difficulty, as well as the importance of algorithms and solvers in finding an optimal solution.

Gurobi created the Burrito Optimization Game in collaboration with Dr. Larry Snyder of Lehigh University, who explains that at the time he and Gurobi started work on the project, there were several other projects in the data science community that used the premise of locating a hypothetical new restaurant. The projects scored possible locations based on demographics, demand, and other data science factors.

“As optimizers, we know it can be easy to pick the single best location once you have a score, but if you need to pick five, ten, or fifty locations, especially when there are thousands to choose from, that becomes a very different kind of problem,” says Dr. Snyder. “So we decided to use this as a way to introduce the optimization story, hoping that the idea of first coming up with a score for each location and then putting that into an optimization context would resonate, even for data scientists who hadn’t seen the restaurant examples.”

Gurobi’s game is based on a classic facility location problem and allows players to choose the best locations for a “Guroble” food truck, with the goal of maximizing their total profit. For each level, players are presented with a new story, with added complexity, and a set of data to help them make decisions. The data provided typically includes the cost of each truck, the price of ingredients, and the total sales revenue for each burrito sold, as well as scenarios that will impact decision-making—such as disruptions in the burrito ingredient supply chain, or weather conditions that impact a customer’s willingness to travel.

Players can drag and drop their Guroble trucks around an illustrated map, where they can see how many customers are in each building. The closer the truck is to a building, the more customers from that building will be willing to walk to the truck to buy a burrito. Players can see how their profits adjust when they drag and drop the truck to a different location, highlighting the importance of trade-offs in complex decision-making.

Once a player is satisfied with their placement of the trucks, Gurobi will solve the problem and find the optimal solution within a fraction of a second. Players can then see how far they were from the optimal solution in terms of total profit.

The game also provides tips along the way to further the learning experience once players submit their solution. For example, players might be notified that a certain part of the city is underserved, or they’ll see a hint that their solution has the optimal number of trucks, but in the wrong locations.

In subsequent rounds, the game introduces uncertainties for an added challenge. Players need to build their solutions based off of forecasts rather than actual demand in this game—a concept that’s very familiar for data science students. For example, there might be 25 potential customers forecast in a building, but the actual amount could be off by up to five customers. Error bars indicate how far in either direction the actual demands might be.

“What we’re hoping to convey is that if you were to try optimization by trial and error, it’s not only tedious and time-consuming, but it’s also hard to make good decisions,” explains Dr. Snyder. “We also wanted to make clear that although optimization is hard, it’s a mature scientific field with robust commercial and open-source software that can solve these problems for us.”

“We launched this a little while ago, and the early feedback has been extremely positive,” explained Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization. “One common response from optimization professionals is excitement about the prospect of having a simple, entertaining way to show the people they work with the sorts of problems optimization can solve and the power that it brings.”

The Burrito Optimization Game is available on Gurobi’s website , accompanied by a series of resources that highlight intended educational takeaways and explain how instructors can teach the game in a classroom setting or how players can use the game on their own.

About Gurobi Optimization

Gurobi produces the world’s fastest and most powerful mathematical optimization solver—the Gurobi Optimizer—which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability. As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support—so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.

Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye